Chronic urticaria (CU)
Conditions
Interventions
Disease-controlled group vs. uncontrolled groups after remibrutinib treatment:None
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years; 2.Patients diagnosed with chronic urticaria by a physician; 3.Patients signed the informed consent form upon enrollment;
Exclusion criteria
Exclusion criteria: 1.Previous use of remibrutinib as an investigational drug in any remibrutinib interventional study at any time; 2.Currently participating in a clinical trial or receiving any experimental treatment; 3.Patients who, based on the physician's clinical judgment, cannot be treated with remibrutinib; 4.Patients who may be unable to complete the entire study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 7-day Urticaria Activity Score (UAS7); | — |
Secondary
| Measure | Time frame |
|---|---|
| Medication adherence;7-day Urticaria Activity Score (UAS7);Urticaria Control Test (UCT);Dermatology Life Quality Index;Safety endpoints;Angioedema Activity Score (AAS7);Angioedema Activity Score (AECT); | — |
Countries
China
Contacts
Public ContactSun Jinglv
Peking Union Medical College Hospital
Outcome results
None listed